Nautilus Biotechnology, Inc.

NasdaqGS NAUT

Nautilus Biotechnology, Inc. Shareholders' Equity for the quarter ending September 30, 2024: USD 223.43 M

Nautilus Biotechnology, Inc. Shareholders' Equity is USD 223.43 M for the quarter ending September 30, 2024, a -19.42% change year over year. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

Nautilus Biotechnology, Inc. Shareholders' Equity for the quarter ending September 30, 2023 was USD 277.27 M, a -14.77% change year over year.
Nautilus Biotechnology, Inc. Shareholders' Equity for the quarter ending September 30, 2022 was USD 325.34 M, a -13.90% change year over year.
Nautilus Biotechnology, Inc. Shareholders' Equity for the quarter ending September 30, 2021 was USD 377.85 M.

Key data

Date	Shareholders' Equity	Minority Interest	Total Equity	Total Stockholders Equity and Liabilities

NasdaqGS: NAUT

Nautilus Biotechnology, Inc.

CEO	Mr. Sujal M. Patel
IPO Date	Aug. 7, 2020
Location	United States
Headquarters	2701 Eastlake Avenue East
Employees	161
Sector	Technology
Industries Big Data 3D Printing Biotechnology Credit Cards & Payments Database Fintech Pharmaceuticals

Description

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.

Key trends

Past 5 years